Choline Bitartrate

Summary

Choline Bitartrate (CHEMBL2105935) is a phase-3 clinical-stage small molecule; indicated across 1 condition including sleep disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 9
• Chemistry: 253.25 Da · C9H19NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105935
Name	Choline Bitartrate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10198924
Molecular formula	C9H19NO7
Molecular weight	253.25
InChIKey	QWJSAWXRUVVRLH-UHFFFAOYSA-M

SMILES: C[N+](C)(C)CCO.C(C(C(=O)[O-])O)(C(=O)O)O

IUPAC name: 2-hydroxyethyl(trimethyl)azanium;2,3,4-trihydroxy-4-oxobutanoate

Also known as: Choline bitartrate, CHOLINE BITARTRATE

Patent coverage: 2,083 distinct patent families (5,364 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,316 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sleep disorder	3	MONDO:0100081	EFO:0008568

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	3
PHASE4	2
Not specified	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01749982	PHASE4	COMPLETED	A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
NCT06200883	PHASE4	COMPLETED	Effects of a Nutraceutic Compound on Cognitive Impairment
NCT06527391	PHASE2/PHASE3	RECRUITING	Choline and Iron Deficiency
NCT04395196	PHASE2	RECRUITING	RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure
NCT05108974	PHASE2	ACTIVE_NOT_RECRUITING	Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study
NCT01149538	PHASE1/PHASE2	COMPLETED	Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure
NCT02735473	PHASE2	COMPLETED	Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders
NCT03039023	Not specified	COMPLETED	Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans
NCT04012177	Not specified	UNKNOWN	Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women - Mumta Pregnant Women Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).